Additional Medication for Unresponsive Asthma
For acute severe asthma unresponsive to high-dose inhaled β2-agonists and systemic corticosteroids, add nebulized ipratropium bromide (0.5 mg) to the β-agonist, and consider intravenous aminophylline (250 mg over 20 minutes) or parenteral β-agonist (salbutamol or terbutaline 250 µg over 10 minutes). 1
Immediate Management Algorithm
When a patient with acute severe asthma fails to respond after 15-30 minutes of high-dose nebulized β-agonists and systemic corticosteroids:
First-Line Additional Therapy
- Add ipratropium bromide 0.5 mg to the nebulized β-agonist treatment 1
- This anticholinergic provides additional bronchodilation through a different mechanism
- Particularly indicated when life-threatening features are present (PEF <33% predicted, silent chest, cyanosis, exhaustion, confusion, or normal/elevated PaCO2)
Second-Line Additional Therapy
If progress remains unsatisfactory despite ipratropium:
- Intravenous aminophylline: 250 mg over 20 minutes 1
- Critical caveat: Do NOT give bolus aminophylline to patients already taking oral theophyllines
- Requires monitoring of serum theophylline concentrations
OR
- Parenteral β-agonist: Salbutamol or terbutaline 250 µg IV over 10 minutes 1
Monitoring Requirements
Continue to measure peak expiratory flow every 15-30 minutes and assess for:
- Deteriorating peak flow
- Worsening or persisting hypoxia (PaO2 <8 kPa) despite 60% oxygen
- Hypercapnia (PaCO2 >6 kPa)
- Exhaustion, confusion, or drowsiness
These features indicate need for intensive care unit transfer 1.
Important Clinical Pitfalls
What NOT to do:
- Antibiotics are unhelpful unless bacterial infection is confirmed 1
- Sedation is absolutely contraindicated 1
- Percussive physiotherapy is unnecessary 1
Context: Chronic Severe Asthma Management
The evidence distinguishes between acute exacerbations (above) and chronic uncontrolled severe asthma. For chronic management when patients remain uncontrolled on high-dose inhaled corticosteroids and long-acting β-agonists, the more recent guidelines 2 recommend:
- Step 5: High-dose ICS plus LABA, and consider omalizumab for allergic patients
- Step 6: Add oral corticosteroids to high-dose ICS/LABA, and consider omalizumab
However, your question specifically addresses acute unresponsive asthma, where the 1993 British Thoracic Society guidelines 1 provide the most direct answer: ipratropium, then aminophylline or parenteral β-agonist.
The strength of this recommendation comes from consistent guideline consensus, though these are older guidelines. The approach remains fundamentally unchanged because the acute management options are limited and these medications address different pathophysiologic mechanisms when standard therapy fails.